KR
Therapeutic Areas
MoonLake Immunotherapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Sonelokimab (M1095) | Hidradenitis Suppurativa (HS) | Phase 3 |
Leadership Team at MoonLake Immunotherapeutics
DJ
Dr. Jorge Santos da Silva
Chief Executive Officer
DC
Dr. Christopher K. Morton
Chief Financial Officer
DA
Dr. Aileen P. Ryan
Chief Development Officer
JG
Jeremy G. Abelson
General Counsel and Corporate Secretary
DK
Dr. Klaus Veitinger
Chairman of the Board of Directors
DS
Dr. Srinivas Akkaraju
Board Member
DS
Dr. Samarth Kulkarni
Board Member